TSE:4151Pharmaceuticals
Is KOMZIFTI’s Early AML Data and CEO Review Altering The Investment Case For Kyowa Kirin (TSE:4151)?
Earlier in December 2025, Kura Oncology and Kyowa Kirin reported Phase 1a/1b data showing a favorable safety profile and encouraging antileukemic activity for KOMZIFTI (ziftomenib) combined with venetoclax and azacitidine in difficult-to-treat acute myeloid leukemia, alongside Kyowa Kirin’s board meeting to consider a change in CEO.
The ASH presentations positioned KOMZIFTI as a potential backbone menin inhibitor therapy in both newly diagnosed and relapsed or refractory AML, underlining...